Ardelyx Stock News

Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.

Ardelyx delivered a surprise profit thanks to strong sales of Ibsrela, its first FDA-approved product. The company has also commenced the launch of Xphozah, which only just received FDA approval two w

Ardelyx, Inc. (NASDAQ:ARDX ) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Mike Raab

Despite 18 months of rising interest rates from the Fed, the U.S. economy held a steady 4.9% growth rate in Q3, defying the gloomier economic predictions from economists and analysts. This robust grow

Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The stock of the company climbs 13%.

Late yesterday, Ardelyx announced that the FDA has approved its first-in-class chronic kidney disease drug Xphozah. The drug adds an important new treatment option for patients on dialysis with hyperp

WALTHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med

Looking at the stock market today is like watching an action movie. One minute the bulls are stampeding and stocks are rising.

Ardelyx (NASDAQ: ARDX ) stock is climbing today after the U.S. Food and Drug Administration (FDA) approved the firm's treatment for excessive phosphate levels in kidney disease patients. Shares of ARD

Ardelyx will almost certainly gain FDA approval for XPHOZAH. The XPHOZAH launch will likely be smoother than Ardelyx's IBSRELA, which is the same drug and gaining traction in IBS. Ozempic won't slow t

Ardelyx Inc. ARDX, -0.58% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney disease.

The U.S. Food and Drug Administration (FDA) has approved Ardelyx's drug to treat high phosphate levels in patients with chronic kidney disease (CKD), the company said on Tuesday, more than two years a

WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med

Ardelyx has only one approved therapy, IBS drug Isbrela. The company saw improved second-quarter financials but is not yet profitable.

Ardelyx shows strong financial health, underpinned by 61% QoQ growth in flagship product Ibsrela and an 18-month cash runway. Japanese approval of tenapanor is a pivotal catalyst, targeting unmet need